Repurposing the antihelmintic mebendazole as a hedgehog inhibitor

Andrew R. Larsen, Ren Yuan Bai, Jon H. Chung, Alexandra Borodovsky, Charles M. Rudin, Gregory J. Riggins, Fred Bunz

Research output: Contribution to journalArticle

Abstract

The hedgehog (Hh) signaling pathway is activated in many types of cancer and therefore presents an attractive target for new anticancer agents. Here, we show that mebendazole, a benzamidazole with a long history of safe use against nematode infestations and hydatid disease, potently inhibited Hh signaling and slowed the growth of Hh-driven human medulloblastoma cells at clinically attainable concentrations. As an antiparasitic, mebendazole avidly binds nematode tubulin and causes inhibition of intestinal microtubule synthesis. In human cells, mebendazole suppressed the formation of the primary cilium, a microtubule-based organelle that functions as a signaling hub for Hh pathway activation. The inhibition of Hh signaling by mebendazole was unaffected by mutants in the gene that encodes human Smoothened (SMO), which are selectively propagated in cell clones that survive treatment with the Hh inhibitor vismodegib. Combination of vismodegib and mebendazole resulted in additive Hh signaling inhibition. Because mebendazole can be safely administered to adults and children at high doses over extended time periods, we propose that mebendazole could be rapidly repurposed and clinically tested as a prospective therapeutic agent for many tumors that are dependent on Hh signaling.

Original languageEnglish (US)
Pages (from-to)3-13
Number of pages11
JournalMolecular cancer therapeutics
Volume14
Issue number1
DOIs
StatePublished - Jan 1 2015

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Repurposing the antihelmintic mebendazole as a hedgehog inhibitor'. Together they form a unique fingerprint.

  • Cite this